New drugs for allergic conjunctivitis.
D000328:Adult; D018926:Anti-Allergic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003233:Conjunctivitis, Allergic / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007665:Ketotifen / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017835:Nedocromil / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011744:Pyrimidinones / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D012220:Rhinitis / Q000139:chemically induced
D018926:Anti-Allergic Agents; D006634:Histamine H1 Antagonists; D011725:Pyridines; D011744:Pyrimidinones; D017835:Nedocromil; C055139:pemirolast; D007665:Ketotifen